Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738553 · ClinicalTrials.gov registry record
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
A clinical trial of HER2-positive Breast Cancer, sponsored by University of Washington.
- Active
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT03738553: Active study of HER2-positive Breast Cancer, sponsored by University of Washington.
NCT03738553 is a study of HER2-positive Breast Cancer that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 13 participants, below the 236-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03738553, a study of HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.
Primary Outcome
Determine whether early changes on MRI reflect the level of immune response (based on TILs) in the tumor as measured by histologic assessment after 1 cycle of anti-HER2 treatment
Conditions Studied
Interventions
- DRUG Trastuzumab
- DEVICE MRI
Study Locations (1)
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-08 |
| Est. Completion | 2026-03 |
What the registry record for NCT03738553 still lists
NCT03738553 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 236-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab is the first listed.
NCT03738553 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03738553 about?
NCT03738553 is a clinical study titled "Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy". This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.
What is the current status of trial NCT03738553?
This trial is currently active not recruiting. The enrollment target is 13 participants. The study started on 2013-08. Estimated completion is 2026-03.
What conditions does trial NCT03738553 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT03738553?
The interventions under investigation include: Trastuzumab (DRUG), MRI (DEVICE).
Who is sponsoring clinical trial NCT03738553?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03738553 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03738553's enrollment target sits among peer trials
13 56th of 58 higher than 3 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia